Loss of smarcad1a accelerates tumorigenesis of malignant peripheral nerve sheath tumors in zebrafish. Issue 11 (7th August 2021)

• Record Type: Journal Article
• Authors: Han, Han; Jiang, Guangzhen; Kumari, Rashmi; Silic, Martin R.; Owens, Jake L.; Hu, Chang‐Deng; Mittal, Suresh K.; Zhang, GuangJun
• Is Part Of: Genes, chromosomes & cancer. Volume 60:Issue 11(2021)
• Page Start: 743
• Page End: 761
• Publication Date: 2021-08-07
• Subjects: CRISPR -- MPNST -- SMARCAD1 -- smarcad1a -- tp53, DNA damage repair -- zebrafish, 4q22‐23; Cancer -- Genetic aspects -- Periodicals; 616.994042
• DOI: 10.1002/gcc.22983
• Languages: English
• ISSNs: 1045-2257

Abstract

Abstract: Malignant peripheral nerve sheath tumors (MPNSTs) are a type of sarcoma that generally originates from Schwann cells. The prognosis for this type of malignancy is relatively poor due to complicated genetic alterations and the lack of specific targeted therapy. Chromosome fragment 4q22‐23 is frequently deleted in MPNSTs and other human tumors, suggesting tumor suppressor genes may reside in this region. Here, we provide evidence that SMARCAD1, a known chromatin remodeler, is a novel tumor suppressor gene located in 4q22‐23. We identified two human homologous smarcad1 genes ( smarcad1a and smarcad1b ) in zebrafish, and both genes share overlapping expression patterns during embryonic development. We demonstrated that two smarcad1a loss‐of‐function mutants, sa1299 and p403, can accelerate MPNST tumorigenesis in the tp53 mutant background, suggesting smarcad1a is a bona fide tumor suppressor gene for MPNSTs. Moreover, we found that DNA double‐strand break (DSB) repair might be compromised in both mutants compared to wildtype zebrafish, as indicated by pH2AX, a DNA DSB marker. In addition, both SMARCAD1 gene knockdown and overexpression in human cells were able to inhibit tumor growth and displayed similar DSB repair responses, suggesting proper SMARCAD1 gene expression level or gene dosage is critical for cell growth. Given that mutations of SMARCAD1 sensitize cells to poly ADP ribose polymerase inhibitors in yeast and the human U2OS osteosarcoma cell line, the identification of SMARCAD1 as a novel tumor suppressor gene might contribute to the development of new cancer therapies for MPNSTs.